These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 9425892)

  • 1. No female embryonic lethality in mice nullizygous for Msh2 and p53.
    Toft NJ; Arends MJ; Wyllie AH; Clarke AR
    Nat Genet; 1998 Jan; 18(1):17. PubMed ID: 9425892
    [No Abstract]   [Full Text] [Related]  

  • 2. Female embryonic lethality in mice nullizygous for both Msh2 and p53.
    Cranston A; Bocker T; Reitmair A; Palazzo J; Wilson T; Mak T; Fishel R
    Nat Genet; 1997 Sep; 17(1):114-8. PubMed ID: 9288110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Female embryonic lethality in Msh2-Trp53 nullizygous mice is strain dependent.
    Cranston A; Fishel R
    Mamm Genome; 1999 Oct; 10(10):1020-2. PubMed ID: 10501974
    [No Abstract]   [Full Text] [Related]  

  • 4. Heterozygosity for p53 promotes microsatellite instability and tumorigenesis on a Msh2 deficient background.
    Toft NJ; Curtis LJ; Sansom OJ; Leitch AL; Wyllie AH; te Riele H; Arends MJ; Clarke AR
    Oncogene; 2002 Sep; 21(41):6299-306. PubMed ID: 12214270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell lineage-specific effects associated with multiple deficiencies of tumor susceptibility genes in Msh2(-/-)Rb(+/-) mice.
    Nikitin AY; Liu CY; Flesken-Nikitin A; Chen CF; Chen PL; Lee WH
    Cancer Res; 2002 Sep; 62(18):5134-8. PubMed ID: 12234974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mouse models for hereditary nonpolyposis colorectal cancer.
    de Wind N; Dekker M; van Rossum A; van der Valk M; te Riele H
    Cancer Res; 1998 Jan; 58(2):248-55. PubMed ID: 9443401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Msh2 deficiency attenuates but does not abolish thiopurine hematopoietic toxicity in msh2-/- mice.
    Krynetskaia NF; Brenner TL; Krynetski EY; Du W; Panetta JC; Ching-Hon P; Evans WE
    Mol Pharmacol; 2003 Aug; 64(2):456-65. PubMed ID: 12869651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene symbol: MSH2. Disease: Hereditary nonpolyposis colorectal cancer.
    Otway R; Tetlow N; Hornby J; Doe WF; Kohonen-Corish MR
    Hum Genet; 2005 May; 116(6):536. PubMed ID: 15991307
    [No Abstract]   [Full Text] [Related]  

  • 9. Gene symbol: MSH2. Disease: Hereditary nonpolyposis colorectal cancer.
    Otway R; Tetlow N; Hornby J; Doe WF; Kohonen-Corish MR
    Hum Genet; 2005 May; 116(6):536. PubMed ID: 15991308
    [No Abstract]   [Full Text] [Related]  

  • 10. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine.
    Berry SE; Davis TW; Schupp JE; Hwang HS; de Wind N; Kinsella TJ
    Cancer Res; 2000 Oct; 60(20):5773-80. PubMed ID: 11059773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MSH2 genomic deletions are a frequent cause of HNPCC.
    Wijnen J; van der Klift H; Vasen H; Khan PM; Menko F; Tops C; Meijers Heijboer H; Lindhout D; Møller P; Fodde R
    Nat Genet; 1998 Dec; 20(4):326-8. PubMed ID: 9843200
    [No Abstract]   [Full Text] [Related]  

  • 12. The ability to engage enterocyte apoptosis does not predict long-term crypt survival in p53 and Msh2 deficient mice.
    Sansom OJ; Clarke AR
    Oncogene; 2002 Aug; 21(38):5934-9. PubMed ID: 12185594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Msh2 DNA mismatch repair gene deficiency and the food-borne mutagen 2-amino-1-methy1-6-phenolimidazo [4,5-b] pyridine (PhIP) synergistically affect mutagenesis in mouse colon.
    Zhang S; Lloyd R; Bowden G; Glickman BW; de Boer JG
    Oncogene; 2001 Sep; 20(42):6066-72. PubMed ID: 11593414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
    Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
    Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Msh-2 suppresses in vivo mutation in a gene dose and lesion dependent manner.
    Sansom OJ; Toft NJ; Winton DJ; Clarke AR
    Oncogene; 2001 Jun; 20(27):3580-4. PubMed ID: 11429706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene symbol: msh2. Disease: MSH2.
    Colombino M
    Hum Genet; 2004 Jul; 115(2):170. PubMed ID: 15300970
    [No Abstract]   [Full Text] [Related]  

  • 17. Gene symbol: msh2. Disease: MSH2.
    Colombino M
    Hum Genet; 2004 Jul; 115(2):171. PubMed ID: 15300972
    [No Abstract]   [Full Text] [Related]  

  • 18. Gene symbol: msh2. Disease: MSH2.
    Colombino M
    Hum Genet; 2004 Jul; 115(2):173. PubMed ID: 15300982
    [No Abstract]   [Full Text] [Related]  

  • 19. Loss of p53 in F-MuLV induced-erythroleukemias accelerates the acquisition of mutational events that confers immortality and growth factor independence.
    Wong KS; Li YJ; Howard J; Ben-David Y
    Oncogene; 1999 Sep; 18(40):5525-34. PubMed ID: 10523829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for Msh2 haploinsufficiency in mice revealed by MNU-induced sister-chromatid exchange analysis.
    Bouffler SD; Hofland N; Cox R; Fodde R
    Br J Cancer; 2000 Nov; 83(10):1291-4. PubMed ID: 11044352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.